Different antiphospholipid antibody (APA) profiles in patients with immune thrombocytopenia (ITP) may affect individual response to ITP-specific treatments, according to a study published in Hematology (2019;24[1]:134-138).
“The relevance of detecting antibodies against anticardiolipin, β2-glycoprotein I (β2gpI) or lupus anticoagulant (LA), collectively called antiphospholipid autoantibodies (APA), in subjects with…ITP…is still a debated issue,” explained investigator Fabrizio Vianello, MD, Hematology and Clinical Immunology Unit, Department of Medicine, Padua University School of Medicine, Italy, and colleagues.
“In particular, whether APA profile may affect the clinical course of ITP is unknown,” they added.
- By Janelle Bradley for Oncology Learning Network
